NCT04871282Phase 2, phase 3Active not recruiting

A Study of AL102 in Patients With Progressing Desmoid Tumors

Study sponsor: Immunome, Inc. · IMNM

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-12-03Actual
Enrollment · participants198Actual
Source updated2026-06-08Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Progression free survival. After: Measure: Part A: Safety and Tolerability - Adverse Events Measure: Part B: Progression free survival (PFS).

Check registry source

· 2 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Oct 2025. After: 3 Dec 2025.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview